Evidence map›Paper›PMID 38397927›Full record

ReviewBiomedicines2024

Abnormalities in the KRAS Gene and Treatment Options for NSCLC Patients with the G12C Mutation in This Gene-A Literature Review and Single-Center Experience.

Anna K Rekowska, Piotr Rola, Agnieszka Kwiatkowska, Magdalena Wójcik-Superczyńska, Michał Gil, Paweł Krawczyk, Janusz Milanowski

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 citations in OpenAlex.

  1. [Advances in Immunotherapy of KRAS-mutated Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025
    Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Anna K RekowskaDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, Poland.ORCID 0000-0002-7454-062X
Piotr RolaDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, Poland.
Agnieszka KwiatkowskaDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, Poland.
Magdalena Wójcik-SuperczyńskaDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, Poland.
Michał GilDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, Poland.
Paweł KrawczykDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, Poland.
Janusz MilanowskiDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, Poland.
Medical University of Lublin · PL

Funding

Medical University of Lublin MG31/2022
6 · The paper itself

Abstract

Mutations in the

Indexed as

immunotherapyKRAS inhibitorsKRAS mutationsnon-small cell lung cancer

Identifiers

PMID38397927
PMCPMC10886466
OpenAlexW4391404663

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.